A strategic partnership has been announced to develop Saudi Arabia’s first fully integrated, modular advanced therapy medicinal product (ATMP) manufacturing campus.
The announcement was made at the ongoing BIO International Convention 2025 in Boston, USA, by the King Faisal Specialist Hospital & Research Centre (KFSHRC) and USA-based Germfree Laboratories.
KFSHRC’s main campus in Riyadh will be home to the new facility, which will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology Strategy, two national initiatives aimed at turning Saudi Arabia into a global hub for life sciences, biomanufacturing, and to become a global biotech hub by 2040.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze